I think that if the broadly effective antiviral prophylactic was truly effective on an individual level, then there could be a reasonable market for it. But the market value would be based on its efficacy at protecting individuals, not on transmission reduction.
Which I think is fine—in the absence of specific incentives to make drugs that reduce transmission, a strategy that involves bringing transmission reduction “along for the ride” on otherwise already-valuable drugs makes sense to me.
I think that if the broadly effective antiviral prophylactic was truly effective on an individual level, then there could be a reasonable market for it. But the market value would be based on its efficacy at protecting individuals, not on transmission reduction.
Which I think is fine—in the absence of specific incentives to make drugs that reduce transmission, a strategy that involves bringing transmission reduction “along for the ride” on otherwise already-valuable drugs makes sense to me.